Jack T. Skinner1, 2, Adrienne N. Dula1, 2, Lori R. Arlinghaus2, Jason Williams2, Megan Strother1, Paul Moots3, Christopher C. Quarles1, 2
1Radiology and Radiological Sciences, Vanderbilt University, Nashville, TN, United States; 2Institute of Imaging Science, Vanderbilt University, Nashville, TN, United States; 3Neurology, Vanderbilt University, Nashville, TN, United States
Clinical approaches for monitoring treatment response in brain tumors often rely on imaging tumor size, which may be insufficient based on early changes in tumor physiology. Interpretation of the effectiveness of anti-angiogenic therapies can be confounded by changes in standard of care images. Quantitative MRI methods assessing blood flow (BF), blood volume (BV), cellularity and permeability were applied in a recurrent glioma patient receiving bevacizumab. A decrease in BF, BV, Ktrans and ADC was observed two weeks post-treatment. Correlation of these changes with tumor size and survival time may help establish these imaging biomarkers as predictors of early treatment response.